New pill could ease painful skin condition for those failed by antibiotics
NCT ID NCT07417917
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase II trial tests QLS12010, an oral capsule, in 102 adults with moderate-to-severe hidradenitis suppurativa (HS), a painful skin condition. The study has two parts: an open-label proof-of-concept phase and a placebo-controlled dose-ranging phase. Participants must have tried and failed or been unable to take antibiotics for HS. The goal is to see if the drug reduces abscesses and inflammatory nodules safely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QLS12010 capsules
- What this could lead to
- If successful, this could lead to a new oral treatment option for people with moderate-to-severe hidradenitis suppurativa who haven't responded to antibiotics.
- What could go wrong
- This is an early Phase II trial with only 102 participants, so results may not apply to everyone. The drug's safety and effectiveness are still unproven, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••